Exhibit 99.1

Contacts:
Investor Relations:	Eric J. Shick Vice President, Investor Relations (908) 277-8413
Media Relations:	Holly P. Glass Vice President, Government and Public Relations (703) 754-2848

BARD ANNOUNCES FOURTH QUARTER RESULTS

REVENUE UP 9 PERCENT AS REPORTED,

12 PERCENT EXCLUDING FOREIGN EXCHANGE

MURRAY HILL, NJ — (January 29, 2009) — C. R. Bard, Inc. (NYSE: BCR) today reported 2008 fourth quarter financial results. Fourth quarter 2008 net sales were $634.2 million, an increase of 9 percent over the prior-year period. Excluding the impact of foreign exchange, fourth quarter 2008 net sales increased 12 percent over the prior-year period.

For the fourth quarter 2008, net sales in the U.S. were $436.3 million and net sales outside the U.S. were $197.9 million, an increase of 11 percent and 4 percent, respectively, over the prior-year period. Excluding the impact of foreign exchange, fourth quarter 2008 net sales outside the U.S. increased 14 percent over the prior-year period.

Net sales for the full year 2008 were $2,452.1 million, an increase of 11 percent over the prior-year period. Excluding the impact of foreign exchange, full year 2008 net sales increased 10 percent over the prior-year period.

For the fourth quarter 2008, net income was $149.4 million and diluted earnings per share were $1.47, an increase of 42 percent and 46 percent, respectively, as compared to fourth quarter 2007 results. Adjusting for items that affect comparability between periods as detailed in the tables below, fourth quarter 2008 net income was $121.1 million and diluted earnings per share were $1.19, an increase of 15 percent and 18 percent, respectively, as compared to fourth quarter 2007 results.

For the full year 2008, net income was $416.5 million and diluted earnings per share were $4.06, an increase of 2 percent and 6 percent, respectively, as compared to full year 2007 results. Adjusting for items that affect comparability between periods, full year 2008 net income was $455.4 million and diluted earnings per share were $4.44, an increase of 13 percent and 16 percent, respectively, as compared to full year 2007 results.

Timothy M. Ring, chairman and chief executive officer, commented, “We are pleased to report strong revenue and earnings results for the fourth quarter and full year 2008. Bard has built a consistent record of performance, delivering adjusted EPS growth above our 14 percent target for six consecutive years. We have achieved this through successful product innovation, a commitment to market leadership and the talent and hard work of our employees around the world. The strength of our broad product portfolio and our healthy financial condition position us well for continued success.”

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our September 30, 2008 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.

Consolidated Statements of Income

(dollars in thousands except per share amounts, unaudited)

	Quarter Ended December 31,					Twelve Months Ended December 31,
	2008		2007			2008		2007
Net sales	$	634,200	$	583,300		$	2,452,100	$	2,202,000
Costs and expenses
Cost of goods sold		243,500		227,700			952,100		864,500
Marketing, selling & administrative expense		179,200		169,700			709,500		644,800
Research and development expense		40,000		36,600			199,100		135,800
Interest expense		3,000		3,100			12,100		11,900
Other expense (income), net		2,700		(7,200	)		29,400		(32,300	)
Total costs and expenses		468,400		429,900			1,902,200		1,624,700
Income from continuing operations before income taxes		165,800		153,400			549,900		577,300
Income tax provision		16,400		48,200			133,400		170,900
Income from continuing operations		149,400		105,200			416,500		406,400
Income from discontinued operations		—		—			—		—
Net income	$	149,400	$	105,200		$	416,500	$	406,400
Basic earnings per share:
Income from continuing operations	$	1.50	$	1.04		$	4.19	$	3.96
Net income per share	$	1.50	$	1.04		$	4.19	$	3.96
Diluted earnings per share:
Income from continuing operations	$	1.47	$	1.01		$	4.06	$	3.84
Net income per share	$	1.47	$	1.01		$	4.06	$	3.84
Wt. avg. common shares outstanding - basic		99,300		101,000			99,500		102,700
Wt. avg. common shares outstanding - diluted		101,900		104,100			102,500		105,900

Product Group Summary of Net Sales

(dollars in thousands, unaudited)

	Quarter Ended December 31,									Twelve Months Ended December 31,
	2008		2007			Change		Constant Currency		2008		2007		Change		Constant Currency
Vascular	$	168,500	$	141,900		19	%	23	%	$	643,100	$	539,600	19	%	17	%
Urology		188,900		176,400		7	%	10	%		708,500		658,900	8	%	7	%
Oncology		163,600		148,000		11	%	13	%		646,600		558,600	16	%	15	%
Surgical Specialties		95,500		96,500		-1	%	1	%		368,200		363,500	1	%	—
Other		17,700		20,500		-14	%	-11	%		85,700		81,400	5	%	5	%
Net sales	$	634,200	$	583,300		9	%			$	2,452,100	$	2,202,000	11	%
FX impact				(16,400	)								22,700
Constant Currency	$	634,200	$	566,900				12	%	$	2,452,100	$	2,224,700			10	%

Reconciliation of Earnings

(dollars in millions except per share amounts, unaudited)

	Quarter Ended December 31, 2008
	Cost of Goods Sold			Research & Development Expense			Other Expense (Income), Net			Income Tax Provision (Benefit)			Net Income (Loss)			Diluted Earnings Per Share
GAAP Basis	$	243.5		$	40.0		$	2.7		$	16.4		$	149.4		$	1.47
Items that affect comparability of results between periods:
Tax adjustment		—			—			—			28.3			(28.3	)
Total		—			—			—			28.3			(28.3	)		(0.28	)
Adjusted Basis	$	243.5		$	40.0		$	2.7		$	44.7		$	121.1		$	1.19
	Quarter Ended December 31, 2007
	Cost of Goods Sold			Research & Development Expense			Other Expense (Income), Net			Income Tax Provision (Benefit)			Net Income (Loss)			Diluted Earnings Per Share
GAAP Basis	$	227.7		$	36.6		$	(7.2	)	$	48.2		$	105.2		$	1.01
Adjusted Basis	$	227.7		$	36.6		$	(7.2	)	$	48.2		$	105.2		$	1.01
	Twelve Months Ended December 31, 2008
	Cost of Goods Sold			Research & Development Expense			Other Expense (Income), Net			Income Tax Provision (Benefit)			Net Income (Loss)			Diluted Earnings Per Share
GAAP Basis	$	952.1		$	199.1		$	29.4		$	133.4		$	416.5		$	4.06
Items that affect comparability of results between periods:
Asset disposition		(3.7	)		—			(36.8	)		5.6			34.9
Purchased research & development		—			(49.3	)		—			18.2			31.1
Reorganization costs		—			—			(1.3	)		0.5			0.8
Gain on asset sale		—			—			0.7			(0.1	)		(0.6	)
Tax adjustments		—			—			—			27.3			(27.3	)
Total		(3.7	)		(49.3	)		(37.4	)		51.5			38.9			0.38
Adjusted Basis	$	948.4		$	149.8		$	(8.0	)	$	184.9		$	455.4		$	4.44
	Twelve Months Ended December 31, 2007
	Cost of Goods Sold			Research & Development Expense			Other Expense (Income), Net			Income Tax Provision (Benefit)			Net Income (Loss)			Diluted Earnings Per Share
GAAP Basis	$	864.5		$	135.8		$	(32.3	)	$	170.9		$	406.4		$	3.84
Items that affect comparability of results between periods:
Purchased research & development		—			(1.6	)		—			0.1			1.5
Tax adjustment		—			—			—			3.7			(3.7	)
Total		—			(1.6	)		—			3.8			(2.2	)		(0.02	)
Adjusted Basis	$	864.5		$	134.2		$	(32.3	)	$	174.7		$	404.2		$	3.82

Notes to Reconciliation of Earnings

• For the fourth quarter 2008, a decrease in the income tax provision as a result of the completion of the U.S. Internal Revenue Service (IRS) examination for the tax years of 2003 and 2004 affected the comparability of results between periods. The effect of this item increased net income by $28.3 million, or $0.28 diluted earnings per share.

• For the fourth quarter 2007, there were no items that affected the comparability of results between periods.

• For the twelve months ended December 31, 2008, the following items affected the comparability of results between periods: (i) a charge of $40.5 million pretax for an asset disposition; (ii) a charge of $49.3 million pretax for purchased research and development; (iii) a charge of $1.3 million pretax for reorganization costs; (iv) a gain of $0.7 million pretax associated with the sale of an asset; and (v) a net decrease of $27.3 million in the income tax provision including a decrease of $28.3 million as a result of the completion of the IRS examination for the tax years of 2003 and 2004, offset by an increase of $1.0 million due to a tax-related interest adjustment. The net effect of these items decreased net income by $38.9 million, or $0.38 diluted earnings per share.

• For the twelve months ended December 31, 2007, the following items affected the comparability of results between periods: (i) a charge of $1.6 million pretax for purchased research and development; and (ii) a decrease in the income tax provision of $3.7 million due to changes in certain statutory tax rates outside the United States that resulted in the revaluation of deferred taxes. The net effect of these items increased net income by $2.2 million, or $0.02 diluted earnings per share.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP financial measures are reconciled to their most directly comparable GAAP measures in the above tables.

This press release includes net sales excluding the impact of foreign exchange. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors.

In addition, this press release includes the following non-GAAP measures: (1) cost of goods sold excluding a charge for an asset disposition; (2) research & development expense excluding payments for purchased research and development; (3) other expense (income), net, excluding charges for an asset disposition, reorganization costs and a gain on an asset sale; (4) income tax provision excluding: a decrease resulting from the completion of the IRS examination for the tax years of 2003 and 2004; an increase due to a tax-related interest adjustment; a decrease related to changes in statutory tax rates; and the tax effect of the items set forth in (1) through (3) above; (5) net income excluding the items set forth in (1) through (4) above; and (6) diluted earnings per share excluding the items set forth in (1) through (4) above.

The company excluded the items described above because they may cause certain statements of income categories not to be indicative of ongoing operating results, and therefore affect the comparability of results between periods. The company therefore believes that these non-GAAP measures provide an additional and meaningful assessment of the company’s ongoing operating performance. Because the company has historically reported these non-GAAP results to the investment community, management also believes that the inclusion of these non-GAAP measures provides consistency in its financial reporting and facilitates investors’ understanding of the company’s historic operating trends by providing an additional basis for comparisons to prior periods. Management uses these non-GAAP measures: (1) to establish financial and operational goals; (2) to monitor the company’s actual performance in relation to its business plan and operating budgets; (3) to evaluate the company’s core operating performance and understand key trends within the business; and (4) as part of several components it considers in determining incentive compensation.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they may not be comparable with similar non-GAAP financial measures used by other companies and that management must exercise judgment in determining which types of charges or other items should be excluded from the non-GAAP financial information. Management compensates for these limitations by providing full disclosure of each non-GAAP financial measure and a reconciliation to the most directly comparable GAAP financial measure. All non-GAAP financial measures are intended to supplement the applicable GAAP disclosures and should not be considered in isolation from, or as a replacement for, financial information prepared in accordance with GAAP. For a reconciliation of these non-GAAP measures to the most comparable GAAP measures, please see the above tables.